Phase 2 trial in OsteoArthritis recently passed using the repurposed drug Pentosan.  Next step will be to run a Phase 3 trial, with potential for a partnering deal.  Their drug has been accessible through the Special Access Scheme here in Australia so may also receive provisional approval prior to P3 completion - so potential for early and substantial revenues which would limit the need for further capital raises.  Several other indications also being pursued with significant potential.  Good IP, safe drug, with special patents over its use, and exclusive supply agreements from only manufacturer of FDA approved product.  Very good quality board with plenty of skin in the game.